APA (7th ed.) Citation

Jia Hu, Jia Hu, Zhuomiao Ye, Zhe Xu, Zhinan Hao, Yongjun Wang, & Yongjun Wang. (2022). Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Jia Hu, Jia Hu, Zhuomiao Ye, Zhe Xu, Zhinan Hao, Yongjun Wang, and Yongjun Wang. Cost-effectiveness Analysis of Pembrolizumab Vs. Chemotherapy as Second-line Treatment for Advanced Esophageal Carcinoma in the United States. Frontiers Media S.A., 2022.

MLA (9th ed.) Citation

Jia Hu, et al. Cost-effectiveness Analysis of Pembrolizumab Vs. Chemotherapy as Second-line Treatment for Advanced Esophageal Carcinoma in the United States. Frontiers Media S.A., 2022.